

RESEARCH BEYOND BORDERS



Research Beyond Borders (RBB) acts as a ‘radar’ for the next big wave of innovation by exploring emerging science and technologies. We are interested in advancing drug discovery in areas of high unmet medical need, or where existing therapies are limited in efficacy, acceptability or applicability. We are agnostic to therapeutic area and modality, and search for new and disruptive ideas and technologies across the research spectrum to create new opportunities and capabilities for drug discovery and development.

Looking beyond our own expertise, we forge collaborations with the scientific community that blend external innovation and internal capabilities.

Specific partnering priorities:

- **Gene Therapy:** Tissue selective AAV capsid variants (focus on eye- and liver-specificity); technology and/or AAV capsid variants which evade pre-existing immunity; expression control systems with ligands suitable for chronic administration; research and early development gene therapy projects with *in-vivo* pre-clinical proof of concept.
- **Regenerative Medicine:** Drug-based modulation of pathways/targets involved in the stimulation of human endogenous cells for tissue regeneration to ultimately restore organ physiological functions (i.e. beta cell regeneration for T2D; hair cell regeneration for age-related hearing loss). Other diseases of interest are sarcopenia, dry AMD and osteoarthritis)
- **Infectious Diseases:** Novel approaches addressing antimicrobial resistance in bacterial and invasive fungal infections (i.e. *S. aureus*, *A. baumannii*, *P. aeruginosa*, *M. tuberculosis* and *Candida spp.*). Viral diseases currently lacking cure (i.e. chronic hepatitis B).

Contact:

Dr. Junjun Gao, USA
junjun.gao@boehringer-ingelheim.com

Dr. Tomoko Maeda, Japan
tomoko.maeda@boehringer-ingelheim.com

Dr. Laura Corradini, Europe
laura.corradini@boehringer-ingelheim.com

Dr. Weiyi Zhang, China
weiyi.zhang@boehringer-ingelheim.com